2024-09-30 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

This report provides an analysis of Johnson & Johnson (JNJ) stock based on the provided data. 

**1. Performance vs. S&P 500 (VOO)**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. Its stock has accumulated a return of 36.05%, compared to the S&P 500 (VOO) which has accumulated a return of 133.28%. 

This indicates that JNJ has **underperformed** the S&P 500 by a substantial margin. The **relative divergence** is currently at -97.23, meaning that it is at the lower end of the historical range, and the **relative divergence** is 7.11, indicating it is within the 7.11 percentile of historical data.

**2. Recent Price Movement**

The current closing price of JNJ is 162.82. 

* **5-day moving average:** 162.08
* **20-day moving average:** 164.91
* **60-day moving average:** 159.96

These moving averages suggest that the stock price has been **trending downward** in the short term.

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 36.9. This indicates that JNJ is currently in **oversold territory**, suggesting potential for a rebound.
* **PPO (Percentage Price Oscillator):** -0.47. A negative PPO indicates that the stock price is **below its moving average** and may be continuing its downtrend.
* **Delta_Previous_Relative_Divergence:** -5.2. This indicates that the **relative divergence** has been decreasing in the past 20 days, signifying a potential **short-term decline**.
* **Expected Return:** 0.0%. This implies that the maximum expected return over the next 5 years is 0% based on the current investment amount.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

The most recent earnings for Q2 2024 were announced on July 25th, 2024. JNJ reported an EPS of 1.95, which **beat analyst estimates** of 1.88. Revenue also exceeded expectations, coming in at 22.45 billion, compared to the expected 22.07 billion.

**5. News and Recent Issues**

Recent market outlook for JNJ remains mixed. While the company continues to dominate the pharmaceutical and consumer health sectors, it faces headwinds from regulatory scrutiny, competition, and declining demand for some of its products. 

Analyst opinions on JNJ are **mixed** with some analysts remaining bullish on the long-term potential of the company, while others express concerns regarding the company's ability to achieve significant growth in the future.

**6. Overall Analysis**

Despite a recent beat on earnings, JNJ remains **underperforming** the broader market, exhibiting a significant **relative divergence** against the S&P 500. 

The stock is in **oversold territory** according to RSI, but the **negative PPO** and **decreasing relative divergence** suggest continued downward pressure. 

While JNJ remains a strong company with a diverse portfolio, its future performance remains uncertain. 

**7. Recommendation**

Investors should proceed with caution given the recent price performance and mixed market sentiment. 

It is recommended to **closely monitor** the stock's price movements and **consider diversifying** investments. 

This analysis provides a summary based on the provided data and does not constitute financial advice. Investors are urged to conduct further research and consult with a financial professional before making any investment decisions.
